Herein we effectively observed improved prognosis in patients with strong CD4/CD68/CSF1R expression suggesting that these immune response signatures may correlate with patient diversity allowing for personalized, precision medicine, leading to OSA-tailored therapeutic strategies. This evidence concerns the gene CD4 and obstructive sleep apnea syndrome.